Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3
Tai-Lung Cha,1,2*Binhua P. Zhou,1Weiya Xia,1Yadi Wu,1Cheng-Chieh Yang,1,2Chun-Te Chen,1Bo Ping,1Arie P. Otte,3Mien-Chie Hung1,2
Enhancer of Zeste homolog 2 (EZH2) is a methyltransferase thatplays an important role in many biological processes throughits ability to trimethylate lysine 27 in histone H3. Here, weshow that Akt phosphorylates EZH2 at serine 21 and suppressesits methyltransferase activity by impeding EZH2 binding to histoneH3, which results in a decrease of lysine 27 trimethylationand derepression of silenced genes. Our results imply that Aktregulates the methylation activity, through phosphorylationof EZH2, which may contribute to oncogenesis.
1 Department of Molecular and Cellular Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. 2 Graduate School of Biomedical Sciences, the University of Texas Health Science Center at Houston, Houston, TX 77030, USA. 3 Swammerdam Institute for Life Sciences, University of Amsterdam, Kruislaan 406, 1098 SM Amsterdam, the Netherlands.
* Present address: Division of Urology, Department of Surgery,Tri-Service General Hospital, National Defense Medical Center,National Defense University, Taipei, 104, Taiwan.
Present address: Sealy Center for Cancer Cell Biology, the Universityof Texas Medical Branch, Galveston, TX 775551048, USA.
To whom correspondence should be addressed. E-mail: mhung{at}mdanderson.org
Effects of Akt signaling on nuclear reprogramming.
T. Nakamura, K. Inoue, S. Ogawa, H. Umehara, N. Ogonuki, H. Miki, T. Kimura, A. Ogura, and T. Nakano (2008)
Genes Cells
13, 1269-1277
|Abstract »|Full Text »|PDF »
Arsenite alters global histone H3 methylation.
X. Zhou, H. Sun, T. P. Ellen, H. Chen, and M. Costa (2008)
Carcinogenesis
29, 1831-1836
|Abstract »|Full Text »|PDF »
Regulators of Cellular Levels of Histone Acetylation in Saccharomyces cerevisiae.
W. Peng, C. Togawa, K. Zhang, and S. K. Kurdistani (2008)
Genetics
179, 277-289
|Abstract »|Full Text »|PDF »
High Histone Acetylation and Decreased Polycomb Repressive Complex 2 Member Levels Regulate Gene Specific Transcriptional Changes During Early Embryonic Stem Cell Differentiation Induced by Retinoic Acid.
E. R. Lee, F. E. Murdoch, and M. K. Fritsch (2007)
Stem Cells
25, 2191-2199
|Abstract »|Full Text »|PDF »
PRDM5 Identified as a Target of Epigenetic Silencing in Colorectal and Gastric Cancer.
Y. Watanabe, M. Toyota, Y. Kondo, H. Suzuki, T. Imai, M. Ohe-Toyota, R. Maruyama, M. Nojima, Y. Sasaki, Y. Sekido, et al. (2007)
Clin. Cancer Res.
13, 4786-4794
|Abstract »|Full Text »|PDF »
Phosphorylation-mediated inactivation of coactivator-associated arginine methyltransferase 1.
K. Higashimoto, P. Kuhn, D. Desai, X. Cheng, and W. Xu (2007)
PNAS
104, 12318-12323
|Abstract »|Full Text »|PDF »
Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma.
C. Lu, T. Bonome, Y. Li, A. A. Kamat, L. Y. Han, R. Schmandt, R. L. Coleman, D. M. Gershenson, R. B. Jaffe, M. J. Birrer, et al. (2007)
Cancer Res.
67, 1757-1768
|Abstract »|Full Text »|PDF »
Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases.
M. A. Bogoyevitch and B. Kobe (2006)
Microbiol. Mol. Biol. Rev.
70, 1061-1095
|Abstract »|Full Text »|PDF »
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
W. Fiskus, M. Pranpat, M. Balasis, B. Herger, R. Rao, A. Chinnaiyan, P. Atadja, and K. Bhalla (2006)
Mol. Cancer Ther.
5, 3096-3104
|Abstract »|Full Text »|PDF »
Dominant-Negative Histone H3 Lysine 27 Mutant Derepresses Silenced Tumor Suppressor Genes and Reverses the Drug-Resistant Phenotype in Cancer Cells.
P. H. Abbosh, J. S. Montgomery, J. A. Starkey, M. Novotny, E. G. Zuhowski, M. J. Egorin, A. P. Moseman, A. Golas, K. M. Brannon, C. Balch, et al. (2006)
Cancer Res.
66, 5582-5591
|Abstract »|Full Text »|PDF »